The Correlation of Medication Adherence To Clinical Outcomes and Quality of Life For Type 2 Diabetes Mellitus Patients Kiki Rawitri, Khairunnisa, Wiryanto
The Correlation of Medication Adherence To Clinical Outcomes and Quality of Life For Type 2 Diabetes Mellitus Patients Kiki Rawitri, Khairunnisa, Wiryanto
The Correlation of Medication Adherence To Clinical Outcomes and Quality of Life For Type 2 Diabetes Mellitus Patients Kiki Rawitri, Khairunnisa, Wiryanto
1
Department of Pharmacology, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia
*Email: [email protected]
ABSTRACT
Objective: This study aimed to determine the relationship between medication adherence to clinical
outcomes and quality of life of type 2 DM patients.
Method: This study used a cross-sectional study design involving 40 types 2 DM patients who met the
inclusion criteria at a community pharmacy in Medan city from August - September 2020. Compliance
level data were obtained using the MMAS-8 (Morisky Medication Adherence Scale-8) questionnaire, data
on random blood glucose levels and HbA1C values were obtained from direct examination of patients,
and data on patient quality of life were obtained using the EQ-5D-3L questionnaire. The data were
analyzed using the Spearman Rho correlation test.
Result: The results showed that the average patient had a low level of adherence with an average HbA1C
value of 9.1%, random blood glucose of 280 mg/dl, and quality of life of 84.7%. The results of the
correlation test showed a significant relationship between the level of adherence and clinical outcome
with a moderate correlation value at random blood glucose (r = -0.591) and a strong correlation value on
HbA1C (r = -0.817). The relationship between the level of adherence and quality of life had a weak
correlation value (r = 0.233), this indicates that the quality of life can improve with increasing medication
adherence.
Conclusion: Based on the results of the study, it can be concluded that the level of patient treatment
adherence greatly affects the clinical outcome and quality of life of type 2 DM patients.